Proteinuria and/or hypertension lead to an increased risk for adverse fetal and maternal outcomes in pregnancy (including PE).11,64 Therapeutic agents that decrease the rate of protein excretion such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor inhibitors have demonstrated teratogenic effects and cannot be used during pregnancy.65,66. The gene discussed is ACE; the disease is Proteinuria.